TY  - GEN
AU  - Fervenza,Fernando C
AU  - Canetta,Pietro A
AU  - Barbour,Sean J
AU  - Lafayette,Richard A
AU  - Rovin,Brad H
AU  - Aslam,Nabeel
AU  - Hladunewich,Michelle A
AU  - Irazabal,Maria V
AU  - Sethi,Sanjeev
AU  - Gipson,Debbie S
AU  - Reich,Heather N
AU  - Brenchley,Paul
AU  - Kretzler,Matthias
AU  - Radhakrishnan,Jai
AU  - Hebert,Lee A
AU  - Gipson,Patrick E
AU  - Thomas,Leslie F
AU  - McCarthy,Ellen T
AU  - Appel,Gerald B
AU  - Jefferson,J Ashley
AU  - Eirin,Alfonso
AU  - Lieske,John C
AU  - Hogan,Marie C
AU  - Greene,Eddie L
AU  - Dillon,John J
AU  - Leung,Nelson
AU  - Sedor,John R
AU  - Rizk,Dana V
AU  - Blumenthal,Samuel S
AU  - Lasic,Lada B
AU  - Juncos,Luis A
AU  - Green,Dollie F
AU  - Simon,James
AU  - Sussman,Amy N
AU  - Philibert,David
AU  - Cattran,Daniel C
TI  - A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR)
SN  - 2235-3186
PY  - 2016///0502
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Angiotensin II Type 1 Receptor Blockers
KW  - therapeutic use
KW  - B-Lymphocytes
KW  - drug effects
KW  - Blood Pressure
KW  - Cyclosporine
KW  - adverse effects
KW  - Endpoint Determination
KW  - Female
KW  - Glomerulonephritis, Membranous
KW  - drug therapy
KW  - Humans
KW  - Immunosuppressive Agents
KW  - Male
KW  - Middle Aged
KW  - Patient Safety
KW  - Proteinuria
KW  - Rituximab
KW  - Treatment Outcome
KW  - Young Adult
N1  - Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1159/000430849
ER  -